N/A N=4 Anti-3-[18F]FACBC Imaging of Parathyroid Adenomas
Parathyroid Disease
Primary: Detection Rate of Parathyroid Adenomas of Anti-3-[18F]FACBC Modality — 80 percentage of adenomas detected
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=13 A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin
Thyroid Neoplasm
Primary: RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment — 6; 1; 1; 0 Participants
Phase 2 N=1,553 Studies of Elevated Parathyroid Activity
Hyperparathyroidism · Hypercalcemia · Parathyroid Neoplasm
Primary: Type of Hyperparathyroidism — 90; 276; 19; 61 Participants
Phase 2 N=90 Central Neck Dissection in Patients With Clinical Node Negative Thyroid Cancer
Stage I Papillary Thyroid Cancer · Stage II Papillary Thyroid Cancer · Stage III Papillary Thyroid Cancer
Primary: Percentage of Participants With Transient Hypoparathyroidism, as Defined by a Day 1 Serum Parathyroid Hormone (PTH) Level of < 10 pg/ml — 24.1; 33.3 percentage of…
N/A N=240 Opioid Use After Thyroid and Parathyroid Surgeries
Thyroidectomy · Parathyroidectomy · Opioid Use
Primary: New Opioid Discharge Prescriptions — 128; 28 Participants
Phase 2 N=12 Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131
Recurrent Thyroid Cancer · Stage IVA Follicular Thyroid Cancer · Stage IVA Papillary Thyroid Cancer
Primary: Restoration of Radioiodine Uptake in Metastatic Lesions as Demonstrated by Diagnostic Whole-body Scanning After Decitabine Administration — 0 participants
Phase 4 N=173 Neurocognitive and Metabolic Effects of Mild Hypothyroidism
Hypothyroidism
Primary: Executive Function — 7.9; 7.5; 8.8 units on a scale
Phase 2 N=3 A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer
Anaplastic Thyroid Cancer · Thyroid Cancer · Differentiated Thyroid Cancer
Primary: Maximum Tolerated Dose (MTD) [Phase I Dose Escalation] — 5 mg
Early Phase 1 N=10 A Pilot Clinical Trial for Poorly Differentiated Thyroid Cancer - Correlation to Retinoid and Peroxisome-proliferator-activated Receptor (PPARy) Expression
Thyroid Cancer
Primary: Change in Tumor Size — 4.7 cm
Phase 2 N=96 Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities
Healthy · Pituitary Disease · Thyroid Disease
Primary: TSH Response to TRH — 11.47 mcIU/mL
Phase 2 N=58 Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer
Metastatic Thyroid Gland Carcinoma · Poorly Differentiated Thyroid Gland Carcinoma · Recurrent Thyroid Gland Carcinoma
Primary: Response at 6 Months — 7; 2 Participants — p=0.0787
Phase 2 N=34 Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer
Thyroid Cancer · Differentiated Thyroid Carcinoma
Primary: The Rate of Successful Thyroid Ablation as Defined by Negative Recombinant Human Thyrotropin (rhTSH) Stimulated Radioiodine Whole Body Scan (RAI WBS) at 1 Year. — 10; 10…
N/A N=34 Generic vs. Name-Brand Levothyroxine
Congenital Hypothyroidism · Hypothyroidism
Primary: Thyroid Stimulating Hormone as Primary Endpoint Measured at Initiation of Study, After 8 Weeks of One Drug, and Then 8 Weeks After the Second Drug. — 2.455; 2.131…
N/A N=160 Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy
Parathyroid Adenoma · Parathyroid Neoplasms · Parathyroid Cancer
Primary: Average Number of Parathyroid Glands Identified — 2.7; 2.6 parathyroid glands per patient — p=.6
N/A N=114 Assessing Benefits of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Total Thyroidectomy
Thyroid Neoplasms · Thyroid Diseases · Hypoparathyroidism
Primary: The Average Number of Parathyroid Glands Identified (Experimental Group: Glands Identified With Naked Eye + NIRAF; Control Group: Glands Identified With Naked Eye) Per…